Pacira BioSciences (PCRX) Common Equity (2010 - 2026)

Pacira BioSciences' Common Equity history runs 17 years deep, the most recent figure standing at $653.9 million for Q1 2026.

• On a quarterly basis, Common Equity fell 18.11% year-over-year to $653.9 million in Q1 2026; TTM through Mar 2026 was $653.9 million, a 18.11% decrease from a year earlier, with the FY2025 full-year figure at $693.1 million, down 10.95% from the prior year.
• Common Equity eased to $653.9 million in Q1 2026 per PCRX's latest filing, from $693.1 million in the prior quarter.
• Across five years, Common Equity topped out at $892.2 million in Q1 2024 and bottomed at $653.9 million in Q1 2026.
• The 5-year median for Common Equity is $770.1 million (2022), against an average of $777.6 million.
• Across the five-year window, Common Equity grew 16.16% in 2024 and declined 18.11% in 2026, its largest moves.
• Year by year, Common Equity stood at $775.0 million in 2022, then advanced by 12.27% to $870.1 million in 2023, then slipped by 10.55% to $778.3 million in 2024, then decreased by 10.95% to $693.1 million in 2025, then slipped by 5.66% to $653.9 million in 2026.
• Per Business Quant, the three latest PCRX Common Equity figures stand at $653.9 million (Q1 2026), $693.1 million (Q4 2025), and $727.2 million (Q3 2025).